Gunjan L Shah - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Gunjan L Shah

Showing results (71-80 of 130) with videos related to

Pageof 13

Sort By:

Blood Cancer Journal|April 12, 2026

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.

Blood Cancer Journal|May 31, 2024

Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.

Blood Cancer Discovery|December 12, 2024

Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaDanny Luan, Susan DeWolf, Teng Fei, et al.

American Journal of Hematology|January 2, 2023

Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.

Blood Advances|August 12, 2020

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.

JCO Oncology Practice|September 16, 2025

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.

Blood Advances|April 10, 2024

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.

Transplantation and Cellular Therapy|July 7, 2024

Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.

Haematologica|November 21, 2024

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.

Pageof 13

Search research articles

Showing results (71-80 of 130) with videos related to

Sort By:

Pageof 13

Blood Cancer Journal|April 12, 2026

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.

Blood Cancer Journal|May 31, 2024

Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.

Blood Cancer Discovery|December 12, 2024

Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell LymphomaDanny Luan, Susan DeWolf, Teng Fei, et al.

American Journal of Hematology|January 2, 2023

Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.

Blood Advances|August 12, 2020

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.

JCO Oncology Practice|September 16, 2025

Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.

Blood Advances|April 10, 2024

Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 6, 2017

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell TransplantationMichael Scordo, Gunjan L Shah, Satyajit Kosuri, et al.

Transplantation and Cellular Therapy|July 7, 2024

Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.

Haematologica|November 21, 2024

Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.

Pageof 13